The US Food and Drug Administration has proposed updating a rule that, among other issues, would clarify that sponsors do not need to claim intended use of their product solely because it has been used off-label by physicians.
In a 22 September proposed rule, the agency hopes to better define what it means by “intended use” and...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?